Evolve Private Wealth LLC Acquires Shares of 12,735 United Therapeutics Corporation $UTHR

Evolve Private Wealth LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 12,735 shares of the biotechnology company’s stock, valued at approximately $6,900,000.

Other institutional investors have also added to or reduced their stakes in the company. Torren Management LLC purchased a new stake in United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC boosted its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 1.5%

Shares of UTHR stock opened at $513.12 on Friday. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The firm’s 50 day moving average is $533.08 and its 200 day moving average is $537.36. The stock has a market capitalization of $22.01 billion, a P/E ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the previous year, the business earned $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,729.06. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 442,575 shares of company stock valued at $239,326,330 in the last three months. 8.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.